
Antony P Martin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9280408/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future. Frontiers in Pharmacology, 2020, 11, 1205.	1.6	143
2	Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: findings and implications for the future. Current Medical Research and Opinion, 2020, 36, 301-327.	0.9	111
3	Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. Frontiers in Public Health, 2018, 6, 328.	1.3	102
4	Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways. Frontiers in Pharmacology, 2016, 7, 305.	1.6	48
5	Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 527-540.	0.7	48
6	Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 1-26.	0.7	47
7	Rapid Assessment of the Potential Paucity and Price Increases for Suggested Medicines and Protection Equipment for COVID-19 Across Developing Countries With a Particular Focus on Africa and the Implications. Frontiers in Pharmacology, 2020, 11, 588106.	1.6	41
8	Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries. Expert Opinion on Pharmacotherapy, 2019, 20, 2237-2255.	0.9	38
9	Pilot study assessing the direct medical cost of treating patients with cancer in Kenya; findings and implications for the future. Journal of Medical Economics, 2018, 21, 878-887.	1.0	37
10	Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation. Frontiers in Pharmacology, 2017, 8, 497.	1.6	34
11	Proposal for a regulation on health technology assessment in Europe – opinions of policy makers, payers and academics from the field of HTA. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 251-261.	0.7	31
12	Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab. Applied Health Economics and Health Policy, 2020, 18, 5-16.	1.0	31
13	Pricing of oral generic cancer medicines in 25 European countries; findings and implications. GaBI Journal, 2019, 8, 49-70.	0.4	31
14	Evidence-based public policy making for medicines across countries: findings and implications for the future. Journal of Comparative Effectiveness Research, 2021, 10, 1019-1052.	0.6	30
15	An assessment of the impact of pharmacogenomics on health disparities: a systematic literature review. Pharmacogenomics, 2017, 18, 1541-1550.	0.6	24
16	Understanding minimum and ideal factor levels for participation in physical activities by people with haemophilia: An expert elicitation exercise. Haemophilia, 2020, 26, 711-717.	1.0	19
17	Evaluating the use of plerixafor in stem cell mobilisation – an economic analysis of the <scp>PHANTASTIC</scp> trial. Journal of Clinical Apheresis, 2016, 31, 434-442.	0.7	13
18	Utilization and Expenditure of Anti-cancer Medicines in Kosovo: Findings and Implications. PharmacoEconomics - Open, 2018, 2, 423-432.	0.9	11

ANTONY P MARTIN

#	Article	IF	CITATIONS
19	Impact of a Clinical Pharmacist Intervention on Medicine Costs in Patients with Chronic Obstructive Pulmonary Disease in India. PharmacoEconomics - Open, 2020, 4, 331-342.	0.9	11
20	Systematic review of the methods used in economic evaluations of targeted physical activity and sedentary behaviour interventions. Social Science and Medicine, 2019, 232, 156-167.	1.8	9
21	Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model. Journal of Medical Economics, 2021, 24, 363-372.	1.0	8
22	Trastuzumab uptake in HER2-positive breast cancer patients: a systematic review and meta-analysis of observational studies. Critical Reviews in Oncology/Hematology, 2018, 130, 92-107.	2.0	6
23	Economic burden of hemophilia B in the US: a systematic literature review. Journal of Drug Assessment, 2019, 8, 28-28.	1.1	6
24	Trends in BRCA testing and socioeconomic deprivation. European Journal of Human Genetics, 2019, 27, 1351-1360.	1.4	6
25	Assessing the effectiveness and cost-effectiveness of drug intervention programs: UK case study. Journal of Addictive Diseases, 2017, 36, 5-13.	0.8	5
26	Examining patient and professional perspectives in the UK for gene therapy in haemophilia. Haemophilia, 2022, 28, 588-609.	1.0	5
27	Consumer willingness to pay for a hypothetical Chagas disease vaccine inÂBrazil: a cross-sectional study and the implications. Journal of Comparative Effectiveness Research, 2021, 10, 659-672.	0.6	4
28	Willingness to pay for a hypothetical malaria vaccine inÂBrazil: a cross-sectional study and the implications. Journal of Comparative Effectiveness Research, 2022, 11, 263-274.	0.6	3
29	The Budget Impact of Monoclonal Antibodies Used to Treat Metastatic Colorectal Cancer in Minas Gerais, Brazil. Applied Health Economics and Health Policy, 2021, 19, 557-577.	1.0	2
30	Disease State Adaptation Experienced By Patients with Hemophilia: Literature Review and Expert Consensus. Blood, 2019, 134, 5801-5801.	0.6	2
31	Examining the uptake of predictive BRCA testing in the UK; findings and implications. European Journal of Human Genetics, 2021, 29, 699-708.	1.4	2
32	COMplex mental health PAThways (COMPAT) Study: A mixed methods study to inform an evidence-based service delivery model for people with complex needs: Study protocol. PLoS ONE, 2022, 17, e0264173.	1.1	1
33	Health state utilities for beta-thalassemia: a time trade-off study. European Journal of Health Economics, 2022, , 1.	1.4	0